| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Myelodysplastic Syndromes | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Myelodysplastic-Myeloproliferative Diseases | |||||
| Myeloproliferative Disorders | |||||
| Preleukemia | |||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Bone Marrow Diseases | |||||
| Disease | |||||
| Hematologic Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Pathologic Processes | |||||
| Precancerous Conditions | |||||
| 4 | Interventions listed in this trial | ||||
| thalidomide | |||||
| 5 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Leprostatic Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Roswell Park Cancer Institute | |||||
| National Cancer Institute (NCI) | |||||
|
